Clinical trials: Kidney Transplant Immunosuppression
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
Immunosuppression
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
- Trial name
- NCT02953873
- Testing
- Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical University of South Carolina
Disorder Related to Renal Transplantation
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
The purpose of this study is to determine whether Campath-1H induction and the associated lymphocyte depletion will permit long-term rejection-free renal allograft survival in the absence of ongoing corticosteroid administration.
- Trial name
- NCT00167661
- Testing
- Campath-1H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.
- Trial name
- NCT00492869
- Testing
- AEB071
- Where
- 41 sites in United States, Belgium and 5 more
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Surveillance Protocol Biopsy
Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney Transplantation
The risk-benefit of surveillance-protocol biopsy (SPBx) in kidney transplantation remains unclear. The study aims to compare outcomes of recipients with SPBx approach to recipients with standard approach which allograft biopsy…
- Trial name
- NCT02294097
- Testing
- Surveillance protocol kidney allograft biopsy
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Kidney Transplantation
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.
- Trial name
- NCT00933231
- Testing
- tacrolimus, Simulect, Cellcept
- Where
- 13 sites in Canada
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
Renal Failure , Chronic, Graft Failure
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression…
- Conditions
- Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft
- Trial name
- NCT06676696
- Testing
- Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Chronic Rejection
New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy
The purpose of this study is to help researchers find out more about a condition called "Chronic Allograft Nephropathy" (CAN). CAN is a complication that sometimes occurs after kidney transplantation and affects the function of…
- Trial name
- NCT00283348
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Virginia Commonwealth University
Intestine Transplantation, Kidney Transplantation
Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®
Parts A \& B: Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to Advagraf® immunosuppression to compare exposure and one year follow-up for safety and efficacy.
- Conditions
- Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation
- Trial name
- NCT01294020
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 16 sites in Belgium, Czechia and 5 more
- Volunteers
- 81 people
- Sponsor
- Astellas Pharma Europe Ltd.
Kidney Transplantation
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients…
- Trial name
- NCT00658359
- Testing
- Cyclosporine, CP-690,550
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 178 people
- Sponsor
- Pfizer
Kidney Transplantation, Mycophenolate Mofetil
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant.
- Trial name
- RIOT (NCT06568549)
- Testing
- Mycophenolate Mofetil (MMF) Maintenance Group, Mycophenolate Mofetil (MMF) Withdrawal Group
- Where
- 3 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Kidney Diseases, Graft Rejection
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
The main aim of this study is to compare the renal function (serum creatinine at 6 months) in the later introduction of tacrolimus or rapamycin based in immunosuppressor regimes with daclizumab, mycophenolate mofetil, and…
- Trial name
- NCT00290069
- Testing
- Tacrolimus, Rapamycin
- Where
- 7 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Sociedad Andaluza de Trasplantes de Organos y Tejidos
Renal Transplant Rejection, Kidney Transplant Failure and Rejection
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus (Envarsus XR) versus twice daily Tacrolimus (Prograf).
- Trial name
- NCT03511560
- Testing
- Tacrolimus Extended Release Oral Tablet, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Immunosuppression, Transplantation, Kidney
Special Access for the Use of Voclosporin for Kidney Transplantation
Voclosporin is an investigational medication previously studied to prevent acute rejection in patients who receive a kidney transplant.
- Trial name
- NCT01236287
- Testing
- Voclosporin
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Kidney Transplantation
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
This is a multicentre, observational, non-interventional, retrospective analysis by chart review.
- Trial name
- NCT00902980
- Testing
- Chart Review
- Where
- 13 sites in Canada
- Volunteers
- 264 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00483756
- Testing
- Cyclosporine, CP-690,550
- Where
- 69 sites in United States, Australia and 13 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplant Rejection, Kidney Transplant
Microbiome and Immunosuppression: The Mission Study
The purpose of this research is to study immunosuppression drugs, certain foods, and how they can change the microbiome (the natural microorganisms inside the body) of the individual taking the immunosuppressive medications.
- Trial name
- MISSION (NCT04953715)
- Testing
- collection of body microbiome
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Type 1 Diabetes, Organ Transplantation
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
This single center phase 2 clinical trial, is designed for confirming the efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with previous kidney transplantation.
- Conditions
- Type 1 Diabetes, Organ Transplantation, Immunosuppression
- Trial name
- NCT01123187
- Testing
- islet transplantation
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Kidney Transplantation
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00263328
- Testing
- Tacrolimus, CP-690,550
- Where
- 27 sites in United States
- Volunteers
- 46 people
- Sponsor
- Pfizer